The global enzyme-linked immunosorbent assays (ELISA) market is expected to gain impetus from the rising incidence of chronic and infectious diseases. This information is published by Fortune Business Insights™ in an upcoming report, titled, “Enzyme-Linked Immunosorbent Assays Market” Share and Global Trend By Test Type (Direct ELISA, Sandwich ELISA, Competitive ELISA, Reverse ELISA), By Application (Immunology, Inflammation, Infectious Diseases, Cancer, Protein Quantification), By End User (Hospitals, Clinical Laboratories, Pharmaceutical Biotechnology Companies, Research Academic Institutions), and Geography Forecast till 2026.” The report further mentions that various technological advancements are taking place in the field of ELISA.
Additionally, the increasing demand for vitro diagnostics and ELISA tests for early detection are projected to propel the ELIS market growth during the forthcoming years.
Request a Sample Copy of the Research Report:
Key Players Aim to Conduct Trials Launch Novel Products to Gain Competitive Edge
Renowned players present in the market are trying to gain the maximum enzyme-linked immunosorbent assays market revenue. They are doing so by launching new innovative products and by conducting multiple research and development activities. Organizations, namely, CDC and WHO, are also participating in unveiling new ELISA test kits to help the doctors in diagnosing diseases. Below are a couple of the latest key industry developments:
- March 2018: BARD1 Life Sciences, a medical technology company, headquartered in Australia, declared that its BARD1-Ovarian test has proved to be a success in providing high accuracy in detecting ovarian cancer. It is a non-invasive diagnostic tool. The company’s independent study examined the strength of the algorithm on 27 healthy controls and 82 ovarian cancers. It is a ELISA-based blood test that can identify ovarian cancer in the early stage. The tool measures the autoantibodies present in the blood in conjunction with the company’s original algorithm to come up with a score that can detect the presence of ovarian cancer.
July 2018: The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) announced the launch of their new version of ELISA test kit called ELISA YF MAC HD. It is required for laboratory confirmation of yellow fever, which is often based on the patient’s dates and places of travel as well as clinical symptoms. The test would enable doctors to identify anti-YFV IgM antibodies that are to be presented in the patient’s body following a vaccine injection and a viral infection. It can also be used for the diagnosis of other diseases, such as HIV or malaria. At present, the ELISA tests available in the market are not readily purchasable. Laboratories will have to get the components of the test from various sources and create their protocols. However, the new kit will be able to develop a standardized platform for yellow fever IgM testing.
An Overview of the Impact of COVID-19 on this Market:
The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.
We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.
For more information in the analysis of this report, visit: